<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927263</url>
  </required_header>
  <id_info>
    <org_study_id>NI071F1(EFC13464)</org_study_id>
    <nct_id>NCT01927263</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 3 Clinical Study of NI-071 in Patients With Rheumatoid Arthritis ―A Double-blind, Active Drug-controlled Study and Long-term Study―</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nichi-Iko Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nichi-Iko Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate similarity between NI-071 and infliximab(the
      comparator) in terms of efficacy in patients with Rheumatoid Arthritis not adequately
      responding to Methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : Changes in DAS28-ESR</measure>
    <time_frame>week 0 to week 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Changes in DAS28</measure>
    <time_frame>week 0 to week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Changes in ACR20, 50, 70</measure>
    <time_frame>week 0 to week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Changes in ACR core-set</measure>
    <time_frame>week 0 to week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Long term safety (Adverse Events, Immunogenicity, etc.)</measure>
    <time_frame>to 54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>NI-071</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NI-071</intervention_name>
    <description>100mg/vial</description>
    <arm_group_label>NI-071</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>100mg/vial</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of RA as defined by the American College Rheumatology (ACR)
             and European League Against Rheumatism (EULAR) criteria (ACR/EULAR 2010)

          2. Patients who received MTX treatment (6- 16mg/week) for 2 weeks for at least 12 weeks
             prior to the screening visit

        Exclusion Criteria:

          1. Patients with a following past History or concomitant diseases

               -  Other Connective tissue disorders which may interfere the efficacy assessment

               -  Chronic or recurrent infectious disease

               -  Demyelinating disease

               -  Congestive heart failure

               -  lymphoproliferative disorder or myelodysplastic syndrome

               -  Malignancy

               -  Interstitial lung disease

          2. Patients with active or latent tuberculosis or history of tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NichiIko Investigational Site</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

